Proximal Tibia Tumour Location and Curettage Are Major Risk
Factors of Local Recurrence in Giant Cell Tumour of Bone

J 2023

Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone

MAHDAL, Michal, Tomáš TOMÁŠ, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ, Peter MÚDRY et. al.

Základní údaje

Originální název

Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone

Autoři

MAHDAL, Michal (203 Česká republika, garant, domácí), Tomáš TOMÁŠ (203 Česká republika, domácí), Vasileios APOSTOLOPOULOS (203 Česká republika, domácí), Dagmar ADÁMKOVÁ (203 Česká republika, domácí), Peter MÚDRY (203 Česká republika, domácí), Iva STANICZKOVÁ ZAMBO (203 Česká republika, domácí) a Lukáš PAZOUREK (203 Česká republika, domácí)

Vydání

Cancers, BASEL, MDPI, 2023, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200 v roce 2022

Kód RIV

RIV/00216224:14110/23:00132519

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers15184664

UT WoS

001079867600001

Klíčová slova anglicky

GCTB; denosumab; targeted treatment; bone; neoplasia

Štítky

14110112, 14110123, 14110321, 14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 2. 2024 09:42, Mgr. Tereza Miškechová

Anotace

V originále

Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.

Návaznosti

MUNI/A/1395/2022, interní kód MU

Název: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

NU22-10-00054, projekt VaV

Název: Nalezení nových terapeutických cílů pro léčbu obrovskobuněčného kostního nádoru

Investor: Ministerstvo zdravotnictví ČR, Nalezení nových terapeutických cílů pro léčbu obrovskobuněčného kostního nádoru, Podprogram 1 - standardní

Citovat

MAHDAL, Michal, Tomáš TOMÁŠ, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ, Peter MÚDRY, Iva STANICZKOVÁ ZAMBO a Lukáš PAZOUREK. Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone. Cancers. BASEL: MDPI, 2023, roč. 15, č. 18, s. 1-10. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers15184664.

@article{2349419,
   author = {Mahdal, Michal and Tomáš, Tomáš and Apostolopoulos, Vasileios and Adámková, Dagmar and Múdry, Peter and Staniczková Zambo, Iva and Pazourek, Lukáš},
   article_location = {BASEL},
   article_number = {18},
   doi = {http://dx.doi.org/10.3390/cancers15184664},
   keywords = {GCTB; denosumab; targeted treatment; bone; neoplasia},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone},
   url = {https://www.mdpi.com/2072-6694/15/18/4664},
   volume = {15},
   year = {2023}
}

TY  - JOUR
ID  - 2349419
AU  - Mahdal, Michal - Tomáš, Tomáš - Apostolopoulos, Vasileios - Adámková, Dagmar - Múdry, Peter - Staniczková Zambo, Iva - Pazourek, Lukáš
PY  - 2023
TI  - Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone
JF  - Cancers
VL  - 15
IS  - 18
SP  - 1-10
EP  - 1-10
PB  - MDPI
SN  - 20726694
KW  - GCTB
KW  - denosumab
KW  - targeted treatment
KW  - bone
KW  - neoplasia
UR  - https://www.mdpi.com/2072-6694/15/18/4664
N2  - Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15-79). The follow-up period was 8.32 years (2-16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19-11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09-9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: -4.00 [95% CI: -6.81 to -1.18]; p < 0.001 and mean difference: -5.36 [95% CI: -3.74 to -6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.
ER  -

MAHDAL, Michal, Tomáš TOMÁŠ, Vasileios APOSTOLOPOULOS, Dagmar ADÁMKOVÁ, Peter MÚDRY, Iva STANICZKOVÁ ZAMBO a Lukáš PAZOUREK. Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone. \textit{Cancers}. BASEL: MDPI, 2023, roč.~15, č.~18, s.~1-10. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers15184664.

Podrobný výpis o publikaci